// Publications
Science that holds up to scrutiny.
Peer-reviewed publications provide an important scientific and clinical foundation for Phoenix Biotechnology’s programs. This page brings together selected company-associated studies, relevant independent research, and links to source records for further review.
// library
Selected Scientific Publications
Human clinical trials
Hong DS, et al. First-in-human study of PBI-05204, an oleander-derived inhibitor of Akt, FGF-2, NF-κB and p70S6K, in patients with advanced solid tumors. Invest New Drugs. 2014;32(6):1204–1212.
ViewRoth MT, et al. A Phase II, single-arm, open-label, Bayesian adaptive efficacy and safety study of PBI-05204 in patients with Stage IV metastatic pancreatic adenocarcinoma. Oncologist. 2020;25(10):e1446–e1450.
ViewMekhail T, et al. Phase 1 trial of Anvirzel™ in patients with refractory solid tumors. Invest New Drugs. 2006;24(5):423–427.
View
Antiviral
Plante KS, et al. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2. Biomed Pharmacother. 2021;138:111457.
ViewNewman RA, et al. Antiviral effects of oleandrin. J Exp Pharmacol. 2020;12:503-515.
ViewHutchison T, et al. The botanical glycoside oleandrin inhibits human T-cell leukemia virus type-1 infectivity and Env-dependent virological synapse formation. J Antivir Antiretrovir. 2019;11(3):184.
ViewSingh S, et al. Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity. Fitoterapia. 2013;84:32–39.
ViewHa DP, et al. Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19. Cell Biosci. 2024;14(1):115.
View
Neuroprotection and neurodegeneration
Dunn DE, et al. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin. J Neurochem. 2011;119(4):805–814.
ViewVan Kanegan MJ, et al. BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin. J Neurosci. 2014;34(3):963–968.
ViewVan Kanegan MJ, et al. Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke. Sci Rep. 2016;6:25626.
View
Oncology: mechanisms and preclinical evidence
Pan Y, et al. PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Invest New Drugs. 2015;33(2):271–279.
ViewColapietro A, et al. The botanical drug PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human glioblastoma, reduces Akt/mTOR activities, and modulates GSC cell-renewal properties. Front Pharmacol. 2020;11:552428.
ViewColapietro A, et al. The botanical drug PBI-05204, a supercritical CO₂ extract of Nerium oleander, is synergistic with radiotherapy in models of human glioblastoma. Front Pharmacol. 2022;13:852941.
ViewVaccaro S, et al. The botanical drug PBI-05204, a supercritical CO₂ extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo. Front Pharmacol. 2022;13:1071176.
ViewChakraborty S, et al. PBI-05204, a supercritical CO₂ extract of Nerium oleander, suppresses glioblastoma stem cells by inhibiting GRP78 and inducing programmed necroptotic cell death. Neoplasia. 2024;54:101008.
ViewYang P, et al. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther. 2009;8(8):2319–2328.
ViewNewman RA, et al. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008;8(1):36–49.
View
Immunomodulation and cytoprotection
Manna SK, et al. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH₂-terminal kinase. Cancer Res. 2000;60(14):3838–3847.
ViewJensen GS, et al. Differential activities of the botanical extract PBI-05204 and oleandrin on innate immune functions under viral challenge versus inflammatory culture conditions. Molecules. 2023;28(12):4799.
ViewDey P, et al. Oleander attenuates hepatic inflammation in a TLR4-independent manner and by favorable modulation of hepatocellular global metabolome that supports cytoprotection. J Ethnopharmacol. 2024;323:117717.
View
Veterinary and animal health
Newman RA, et al. Efficacy of oleandrin and PBI-05204 against bovine viruses of importance to commercial cattle health. Antivir Chem Chemother. 2022;30:20402066221103960.
ViewNewman RA, et al. Efficacy of oleandrin and PBI-05204 against viruses of importance to commercial pig health management. Front Anim Sci. 2024;5:1359681.
ViewFossum TW, Newman RA, Matos JR. Preliminary investigation of the safe dose of oleandrin when administered orally to Beagles. J Am Vet Med Assoc. 2024;262(7):966–972.
ViewFossum TW, et al. Botanical oleander extract and oleandrin have superior effects on innate immune functions pertaining to dermal allergic reactions in canine cells when compared to oclacitinib. Am J Vet Res. 2024;85(12):ajvr.24.05.0153.
View
Analytical methods and pharmacokinetics
// independent
Independent research worldwide
In addition to Phoenix-associated studies, researchers at institutions worldwide have published peer-reviewed work examining oleandrin and related biological mechanisms.
University of Seville
View publication
Tianjin University of Traditional Medicine
View publication
Liaoning Cancer Hospital & Institute
View publication
University of Bucharest
View publication
Jining Medical University
View publication
Federal University of Goias
View publication
CSIR-Central Drug Research Institute
View publication
Jinnah Sindh Medical University
View publication
North Orissa University
View publication
Government College University Faisalabad
View publication
Bezmialem Vakif University
View publication
Marmara University
View publication
// collaborators
Collaborators
Research supporting Phoenix’s programs has involved institutions and organizations across government, academia, and specialized research, including:
- U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
- Duke University
- The University of Texas MD Anderson Cancer Center
- Johns Hopkins
- U.S. Centers for Disease Control and Prevention (CDC)
- World Reference Center for Emerging Viruses and Arboviruses
- University of Texas Medical Branch
- Southern Methodist University
- Texas Biomedical Research Institute
- NIS Labs
